AstraZeneca Korea accepts price cut of Iressa

AstraZeneca Korea said on November 24 it would not to appeal the ruling of the Seoul Administration Court, while accepting the readjusted price of Iressa (gefitinib) at 55,003 won per tablet to avoid any confusion of patients and doctors.

The court ruled on November 8 that the clinical efficacy of Iressa had not been proved in the local phase III studies, although its novelty in term of mech...